European Union - English - EMA (European Medicines Agency)

theravia - hydroxycarbamide - anemia, sickle cell - antineoplastic agents - siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - metronidazole, quantity: 7.5 mg/g - gel - excipient ingredients: carbomer 974p; propylene glycol; sodium hydroxide; disodium edetate; propyl hydroxybenzoate; methyl hydroxybenzoate; purified water - zidoval vaginal gel 0.75% is indicated in the treatment of symptomatic bacterial vaginosis (formerly referred to as haemophilus vaginalis vaginitis, gardnerella vaginalis vaginitis, non-specific vaginitis, corynebacterium vaginale vaginitis or anaerobic vaginosis). note: for purpose of this indicated, a clincial diagnosis of bacterial vaginosis is usually defined by the presence of at least three of the following four criteria: a) vaginal discharge ph of greater than 4.5, b) a vaginal discharge emitting a "fishy" amine odour when mixed with a 10% koh solution, c) a vaginal discharge containing clue cells on wet mount microscopy examination, d) a gram stain consistent with a diagnosis of bacterial vaginosis (lactobacillus morphotype absent of markedly decreased, gardnerella morphotype predominant flora, white blood cells absent or few, mobiluncus morphotype may or may not be present). a diagnosis of bacterial vaginosis requires that other pathogens which may be associated with genital infection, such as trichomonas vaginalis, candida albicans, chlamydia trachomatis and neisseria gonorrhoeae, should be ruled out be appropriate laboratory means.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - clindamycin phosphate, quantity: 22.8 mg/g (equivalent: clindamycin, qty 20 mg/g) - cream - excipient ingredients: purified water; polysorbate 60; benzyl alcohol; stearic acid; cetyl esters wax; propylene glycol; liquid paraffin; sorbitan monostearate; cetostearyl alcohol - dalacin v cream 2% is indicated for the treatment of symptomatic bacterial vaginosis. note: for the purposes of this indication bacterial vaginosis is usually defined by positive results to at least three of the four following criteria: 1. vaginal discharge with ph > 4.5; 2. vaginal discharge demonstrating an amine ("fishy") odour with the addition of 10% potassium hydroxide; 3. vaginal discharge with "clue cells" on microscopy, and; 4. a gram stain consistent with a diagnosis of bacterial vaginosis (lactobacillus morphotype absent or markedly decreased; gardnerella morphotype predominant flora; white blood cells absent or few; mobiluncus morphotype may or may not be present). other pathogens which may be associated with genital infection such as trichomonas vaginalis, candida albicans, chlamydia trachomatis and neisseria gonorrhoeae should be ruled out by appropriate laboratory means.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; silicon dioxide; kaolin; maize starch - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 40 mg/ml - oral liquid - excipient ingredients: sorbitol; sodium propyl hydroxybenzoate; sodium methyl hydroxybenzoate; saccharin sodium; brilliant scarlet 4r; purified water; sucrose; flavour - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: citric acid monohydrate; hypromellose; polyvinyl acetate phthalate; diethyl phthalate; purified talc; hyprolose; titanium dioxide; povidone; magnesium stearate; amaranth aluminium lake; calcium silicate; indigo carmine aluminium lake; stearic acid; macrogol 6000 - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sodium valproate, quantity: 200 mg - tablet, enteric coated - excipient ingredients: hypromellose; stearic acid; indigo carmine aluminium lake; purified talc; calcium silicate; citric acid monohydrate; amaranth aluminium lake; macrogol 6000; povidone; hyprolose; titanium dioxide; diethyl phthalate; polyvinyl acetate phthalate; magnesium stearate - epilepsy: primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy. mania: for the treatment of mania where other therapy has proved inadequate or is inappropriate

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: triethyl citrate; citric acid; magnesium stearate; sodium starch glycollate; purified talc; povidone; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; indigo carmine; sunset yellow fcf; allura red ac; macrogol 3350 - epilepsy. primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.. mania. for the treatment of mania where other therapy has proved inadequate or is inappropriate.